The hunt for a successor to lithium for bipolar disorder
Advertisement
Toxicity problems and adverse side effects when taking lithium, the mainstay medication for treating bipolar disorder, are fostering a scientific hunt for insights into exactly how lithium works in the body — with an eye to developing a safer alternative, published in the current edition of Chemical & Engineering News (C&EN).
Bethany Halford, C&EN senior editor, explains that lithium often is the first-line medication used to calm the highs and boost the lows of bipolar disorder, which affects about 9 million people at some point in their lives in the United States alone. Lithium has distinct advantages over the dozen or so other medications. For instance, lithium is the only medication proven effective in preventing suicide in the mania phase of bipolar disorder. Lithium also is inexpensive.
The article explains, however, that lithium also has drawbacks, with a fine line between the effective dose and the toxic dose. Side effects include thyroid problems, weight gain and, in some cases, kidney failure. In the hope of skirting lithium's limitations, scientists are trying to pinpoint exactly how lithium stabilizes mood and how it engenders those unwanted effects. The goal is development of a second-generation successor without lithium's downsides, and Halford describes how scientists are working to do so.
Most read news
Other news from the department science

Get the chemical industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
ECHA and stakeholders set out actions to improve chemical safety reports and safety data sheets

“Tamed” Molecules for More Sustainable Catalysts - Successful synthesis of a spectacular gallium compound in the laboratory
Air Liquide has just signed a long-term contract with EMZ, a subsidiary of Metinvest
Messer topping-out ceremony for second production facility in Germany
ZEISS: Significant Growth in Revenue and Earnings - Demand for digital solutions increases

Bayer MaterialScience takes over Czech polyurethane systems house Brahe - Strengthening systems business in the growth region of central and eastern Europe
Rockwell Automation Reports First Quarter 2012 Results and Reaffirms Guidance
Sanofi-aventis And Bristol-Myers Squibb Announce Agreement To Settle U.S. Plavix Litigation With Apotex

A place in the sun - German Federation for applied Photocatalysis (FAP) launched

Verband Schmierstoff-Industrie e.V. (VSI) - Hamburg, Germany
LANXESS expands dichlorobenzene capacity by 15 percent at Leverkusen facility
